INmune Bio and Quantum Computing begin Stage 1 collaboration using Dirac-3S to explore new indications for XPro

INmune Bio and Quantum Computing have launched a Stage 1 collaboration to apply QCi’s Dirac-3S quantum optimization machine, together with artificial intelligence and conventional data analytics, to INmune Bio’s research on XPro (XPro1595).

The partners said the work will draw on INmune Bio’s data spanning preclinical studies and four clinical trials to search for new potential indications and biomarkers for XPro, an investigational therapy that the company is developing for Alzheimer’s disease and other conditions.

QCi characterised the engagement as its first commercial customer in the pharmaceutical and biotechnology sector and framed the project as an entry for its Dirac-3S system into drug research work.

According to the companies’ announcements, the collaboration aims to combine INmune Bio’s clinical research and disease-biology expertise with QCi’s quantum optimisation machine and analytical tools to examine patient populations and biomarkers that might predict treatment response.

INmune Bio Chief Executive Officer David Moss said the partnership will allow the company “to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets,” a comment included in the reporting of the announcement.

Both outlets covering the announcement describe the technical approach in similar terms: Dirac-3S will be used alongside AI and more conventional data analytics to interrogate the combined datasets. The reporting notes that the INmune Bio dataset stretches from preclinical research through four clinical trials, providing a broad set of inputs for computational analysis.

Quantum Computing’s characterization of the Stage 1 engagement as its first commercial pharmaceutical customer appears in the companies’ statements and is repeated across the coverage.

The published pieces do not include detailed timelines for the project beyond labelling the work as a Stage 1 engagement, nor do they provide specifics about budgets, ownership of resulting intellectual property, or the precise analytic methods QCi will run on named datasets.

Neither source reports projected milestones, regulatory filings tied to the collaboration, nor patient-level results; they confine their coverage to the announced technical collaboration and the companies’ descriptions of its aims.

Public comments quoted in the available reporting come from INmune Bio’s chief executive and from the firms’ joint description of the project; no independent external expert commentary or peer-reviewed data supporting the effectiveness of Dirac-3S in drug-indication discovery is cited in the pieces.

The coverage treats Quantum Computing’s claim of a first commercial pharmaceutical customer as the company’s description of the engagement rather than an independently verified market fact.

Investors or industry observers reading these releases will note the emphasis on data scale and computational approach: INmune Bio’s multi-trial dataset and QCi’s Dirac-3S hardware and AI software are presented as complementary assets intended to identify biomarkers and patient subgroups for XPro.